Menu Search
Equities

Zhejiang Taimei Medical Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2576:HKG.HZ

Zhejiang Taimei Medical Technology Co Ltd

Actions
  • Price (HKD)4.86
  • Today's Change-0.03 / -0.61%
  • Shares traded63.00k
  • 1 Year change+35.00%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zhejiang Taimei Medical Technology Co Ltd is a China-based company mainly engaged in the provision of digital solutions for the research and development and commercialisation of pharmaceutical and medical device. The Company mainly designs and provides industry-specific software and digital services to a variety of stakeholders in the pharmaceutical and medical device industry. The Company's cloud-based software mainly provides software as a service (SaaS) products and customized products as well as related technical support, including TrialOS, a digital collaboration platform for the research and development of pharmaceutical and medical device, and PharmaOS, a digital collaboration platform for pharmaceutical and medical device commercialization. The Company's digital services mainly include digital clinical research services and independent reading center (IRC) services. The Company principally conducts its businesses in domestic and overseas markets.

  • Revenue in HKD (TTM)--
  • Net income in HKD--
  • Incorporated2013
  • Employees656.00
  • Location
    Zhejiang Taimei Medical Technology Co Ltd3/F, Building 9,Smart Industry Innovation Park, 36 ChanJiaxing ChinaCHN
  • Websitehttps://www.taimei.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.